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Childhood body mass index and height and risk of histologic
subtypes of endometrial cancer
J Aarestrup1, M Gamborg1, LG Ulrich2, TIA Sørensen1,3 and JL Baker1,3
BACKGROUND: Endometrial cancer risk factors include adult obesity and taller stature, but the inﬂuence of size earlier in life is
incompletely understood. We examined whether childhood body mass index (BMI; kg m− 2) and height were associated with
histologic subtypes of endometrial cancer.
METHODS: From the Copenhagen School Health Records Register, 155 505 girls born 1930–1989 with measured weights and
heights from 7 to 13 years were linked to health registers. BMI and height were transformed to age-speciﬁc z-scores. Hazard ratios
(HRs) and 95% conﬁdence intervals were estimated by Cox regressions.
RESULTS: A total of 1020 endometrial cancers were recorded. BMI was non-linearly associated with all endometrial cancers,
oestrogen-dependent cancers and the subtype of endometrioid adenocarcinomas; associations were statistically signiﬁcant and
positive above a z-score = 0 and non-signiﬁcant below zero. Compared with a 7-year-old girl with a BMI z-score = 0, an equally tall
girl who was 3.6 kg heavier (BMI z-score = 1.5) had a hazard ratio = 1.53 (95% conﬁdence interval: 1.29–1.82) for endometrioid
adenocarcinoma. BMI was not associated with non-oestrogen-dependent cancers, except at the oldest childhood ages. Height at all
ages was statistically signiﬁcant and positively associated with all endometrial cancers, except non-oestrogen-dependent cancers.
At 7 years, per ~ 5.2 cm (1 z-score), the risk of endometrioid adenocarcinoma was 1.18 (95% conﬁdence interval: 1.09–1.28). Among
non-users of unopposed oestrogens, associations between BMI and endometrioid adenocarcinoma strengthened, but no effects on
height associations were observed.
CONCLUSIONS: Endometrial carcinogenesis is linked to early-life body size, suggesting that childhood BMI and height may be
useful indicators for the risk of later development of endometrial cancer and might aid in the early prevention of obesity-related
endometrial cancers.
International Journal of Obesity (2016) 40, 1096–1102; doi:10.1038/ijo.2016.56
INTRODUCTION
Endometrial cancer is the most common gynaecologic cancer
among women in the Western world.1–3 Excess body fatness in
adulthood is consistently and strongly linked to an increased risk
of endometrial cancer among both pre- and post-menopausal
women.1,2,4–7 It is estimated that 34% of the global burden of
incident endometrial cancer is attributable to excess adult
adiposity.8
Aetiologically, endometrial cancer is a heterogeneous cancer.9
Oestrogen-dependent cancers (type 1) account for ~ 80% of
endometrial cancers, of which endometrioid adenocarcinoma is
the predominant form and the prototype. Non-oestrogen-
dependent cancers (type 2) are less common and account for
~ 20% of endometrial cancers.10–12 Adiposity is thought to
increase the risk of oestrogen-dependent endometrial cancers
through an augmented bioavailability of endogenous oestrogens
produced by aromatisation of androgens in adipose tissue.13
Although less attention has been given to adult stature, evidence
suggests that height may increase the risk of endometrial cancer,
but speciﬁc mechanisms are unknown.1,4,14
It is possible that the initiation of endometrial cancer begins
early in life; however, associations between early-life body size and
subsequent risk of endometrial cancer are inconsistent. Although
several studies found indications of positive associations with
child and adolescent body size, all used self-reported recalled
body size and histological subtypes of endometrial cancer were
not examined.15–24 A few studies examined associations with child
height,19,21,23 but only one found a signiﬁcant and positive
association.23 Therefore, we investigated whether childhood body
mass index (BMI; kg m−2) and height were associated with the risk
of histological subtypes of endometrial cancer in a population-
based cohort.
SUBJECTS AND METHODS
Cohort
The study population was from the Copenhagen School Health Records
Register, which contains computerised information on 372 636 children.
Virtually, all school children in the municipality of Copenhagen, born 1930–
1989, underwent annual mandatory health examinations through 1983
and thereafter only at school entrance and exit, unless the child had
speciﬁc health requirements. Heights and weights were measured by
trained school physicians and nurses with high precision.25
Unique government-issued personal identiﬁcation numbers were
assigned to all Danish residents alive in 1968 or born thereafter.26 Children
who attended school in 1968 or later had their identiﬁcation number
recorded on their health card. If a child left school before this time, the
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number was retrieved. Via these identiﬁcation numbers, linkages were
made to national health registers for follow-up.
Study variables
Using the Lamda, Median, Sigma method, BMI and height were
transformed into z-scores.27 BMI z-scores were based upon an internal
age- and sex-speciﬁc reference chosen from a period with a low and stable
obesity prevalence. Height z-scores were based upon internal sex-, age-
and birth cohort-speciﬁc references to account for secular increases in
height. Z-scores were interpolated or extrapolated within a ± 12-month
period.28
Incident endometrial cancers were identiﬁed through linkage to the
Danish Cancer Registry, which contains information on cancers from 1943
onwards.29 The majority of the cancers are morphologically veriﬁed, and
due to compulsory notiﬁcation, the completeness of the registry is
high.29,30 The International Classiﬁcation of Disease (ICD) codes version 7
was used until 1994 and version 10 thereafter. Danish Cancer Registry
personnel recoded all cancers diagnosed between 1978 and 2004 to
ICD-10 and ICD for Oncology codes (ICD-O) version 3.29
Endometrial cancers were classiﬁed using ICD-10 codes C54.0–C54.1,
C54.3–C54.6, C54.9 and C55.9. On the basis of ICD-O-3 morphology codes,
sarcomas, carcinoma–sarcomas, very rare endometrial cancers and cancers
without information on morphology were excluded from all analyses. The
remaining cancers were classiﬁed as oestrogen dependent or non-
oestrogen dependent, except for a few cancers that could not be classiﬁed
due to limited morphology information (Table 1).
Vital status was obtained by linkage to the Vital Statistics Register.26
Hysterectomy information was obtained by linkage to the Danish National
Patient Register, which was established in 1977 and contains information
on all hospital discharge diagnoses.31 Information on hormone replace-
ment therapy usage was obtained through linkage to the Danish National
Prescription Registry, which contains the data on all prescriptions
dispensed by Danish pharmacies from 1995 onwards.32 Unopposed
oestrogens were identiﬁed using Anatomical Therapeutic Chemical
classiﬁcation codes (G03CA03 (oestradiol), G03CA04 (oestriol), G03CA53
(oestradiol, combinations), G03CA57 (conjugated oestrogens) and trade
names). Women were classiﬁed as using unopposed oestrogens if
prescriptions were reﬁlled at least twice.
Study population
Women eligible for this study were born 1930–1989, with an identiﬁcation
number, alive and living in Denmark on 1 January 1978 and aged 18 years
or older. Among 184 276 girls in the cohort, 21 717 did not have an
identiﬁcation number (as identiﬁcation numbers could not be retrieved for
all leaving school before 1968 due to, for example, death, emigration,
name changes and possible spelling errors) and 3808 were excluded due
to emigration, death or loss to follow-up before age 18 years or 1 January
1978. In addition, women with a hysterectomy before 1978 (N= 525) or
age 18 years (N=5), with an endometrial cancer diagnosis before 1978
(N= 10), without a date for the endometrial cancer diagnosis (N= 1),
missing height and/or weight measurements at all childhood ages
(N= 2701) or with outlying height or BMI z-scores at all ages (z-score less
than − 4.5 or greater than 4.5; N= 4) were excluded.
Each woman was followed from the age of 18 years or from her age in
1978, whichever came later. Individuals were followed up until a diagnosis
of endometrial cancer, hysterectomy, death, emigration, loss to follow-up
or 31 December 2012, whichever came ﬁrst.
Statistical analysis
Cox proportional hazards regressions were used to examine associations
between BMI and height z-scores, with and without mutual adjustment, at
each age from 7 to 13 years and the risk of all endometrial cancers,
oestrogen-dependent cancers, endometrioid adenocarcinomas and non-
oestrogen-dependent cancers, respectively. Age at diagnosis was the
underlying time scale, and analyses were stratiﬁed by 5-year birth cohorts
to allow the baseline hazard to differ by birth cohort.
The linearity of the associations was assessed by linear splines with two
knots at z-scores of ± 0.68 corresponding to ~ 25th and 75th percentiles of
the distributions. Statistically signiﬁcant non-linearity was detected for
associations between BMI and all endometrial cancers, oestrogen-
dependent cancers and endometrioid adenocarcinomas, except at ages
12–13 years. Nonetheless, the overall pattern from the younger ages
remained and the results are therefore presented using non-linear models.
To facilitate interpretation, point estimates are presented for z-scores of
± 0.5, ± 1.0 and ± 1.5 (corresponding to ~ 7th, 16th, 31st, 69th, 84th and
93rd percentiles) with a z-score of 0 as reference. Deviations from linearity
were not detected in the associations between BMI and non-oestrogen-
dependent cancers or between height and all endometrial cancers (except
at ages 10–13 years), oestrogen-dependent cancers (except at ages 10–13
years), endometrioid adenocarcinomas and non-oestrogen-dependent
cancers. Upon inspection, the signiﬁcant deviations from linearity revealed
only a tendency for a levelling-off in the increased risk among the tallest
girls, therefore results are presented using the linear models.
Proportional hazards assumptions were investigated by testing if
associations between BMI and height, respectively, and endometrial
cancer differed within categories of age at diagnosis using likelihood ratio
tests. In addition, potential interactions of birth cohort with the
associations between BMI and height, respectively, and endometrial
cancers were investigated using likelihood ratio tests. Violations of the
proportional hazards assumption and birth cohort effects were not
detected.
To examine the inﬂuence of unopposed oestrogen usage on associa-
tions between childhood body size and endometrioid adenocarcinoma, a
sub-analysis was conducted following women from 1995 onwards. Women
were followed until unopposed oestrogen usage, a diagnosis of
endometrial cancer, hysterectomy, death, emigration, loss to follow-up or
31 December 2012, whichever came ﬁrst.
Population-attributable fractions (PAFs) were calculated to estimate the
burden of endometrial cancers attributable to childhood overweight
(including obesity) in a contemporary population of girls from the United
States.
This study was approved by the Danish Data Protection Agency.
According to Danish law, ethical approval is not required for register-based
studies.
RESULTS
The study included 155 505 women. During 35 years and 4.1
million person-years of follow-up, 1020 women were diagnosed
with endometrial cancer. Among these, 920 were oestrogen-
dependent cancers (of which 659 were endometrioid adenocarci-
noma), 92 were non-oestrogen-dependent cancers and 8 cancers
were not classiﬁed as either type. The median age at diagnosis
was 61 years (range: 24–82) for all endometrial cancers, 61 years
(range: 24–82) for oestrogen-dependent cancers, 62 years (range:
24–82) for endometrioid adenocarcinomas and 66 years (range:
38–79) for non-oestrogen-dependent cancers. The median values
of both childhood BMI and height increased with age in childhood
(Supplementary Table 1).
Childhood BMI was non-linearly associated with all endometrial
cancers, oestrogen-dependent cancers and the subtype of
endometrioid adenocarcinoma. At all childhood ages, girls with
a BMI z-score above 0 had a higher risk of all endometrial cancers,
oestrogen-dependent cancers and endometrioid adenocarcinoma
compared with girls with a BMI z-score of 0 (Figure 1;
Supplementary Table 2). Adjusting these associations for height
only slightly attenuated the risk estimates (Supplementary Table 3).
In contrast, BMI values below 0 were not associated with these
cancers (Figure 1; Supplementary Tables 2 and 3). Few women
were diagnosed with non-oestrogen-dependent cancers, and
even though positive and statistically signiﬁcant associations with
childhood BMI were found at ages 12 and 13 years, the conﬁdence
intervals were wide (Table 2).
Childhood height was signiﬁcantly positively associated with all
endometrial cancers, oestrogen-dependent cancers and endome-
trioid adenocarcinoma (Figure 2; Supplementary Table 4). Adjust-
ing for childhood BMI slightly attenuated the associations, but
they remained statistically signiﬁcant (Figure 2; Supplementary
Table 4). Childhood height was non-signiﬁcantly, but positively
associated with non-oestrogen-dependent endometrial cancers
(Figure 2; Supplementary Table 4).
We investigated whether unopposed oestrogen usage modiﬁed
the associations between childhood body size and endometrioid
adenocarcinoma. Of the 140 044 women followed from 1995
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onwards, 8278 used unopposed oestrogens. There were 534
endometrioid adenocarcinomas among non-users and 74 among
users of unopposed oestrogens. In this subsample, results were
similar to those in the full-sample analyses on childhood BMI and
endometrioid adenocarcinomas (Table 3; Supplementary Table 5).
Among non-users of unopposed oestrogens, the estimates in
analyses unadjusted and adjusted for height seemed to
strengthen, but the overall pattern of associations did not change
(Table 3; Supplementary Table 5). Correspondingly, in this
subsample, the childhood height associations were similar to
those in the full sample (Supplementary Table 6). Among non-
users of unopposed oestrogens, the estimates between childhood
height and endometrioid adenocarcinoma were not affected
(Supplementary Table 6).
DISCUSSION
In this large prospective cohort study, we found that girls with a
BMI value above average at each age from 7 to 13 years
experienced a signiﬁcantly higher risk of all endometrial cancers,
oestrogen-dependent cancers and the oestrogen-dependent
subtype of endometrioid adenocarcinoma compared with girls
of average size, whereas associations were not found among girls
with BMI values below average. In contrast, associations between
childhood BMI and non-oestrogen-dependent cancers were not
identiﬁed except at ages 12–13 years and conﬁdence intervals
were broad. Childhood height was signiﬁcantly and positively
associated with all endometrial cancers, oestrogen-dependent
cancers and endometrioid adenocarcinoma, but not with non-
oestrogen-dependent cancers. Among non-users of unopposed
oestrogens, associations between BMI and endometrioid adeno-
carcinoma seemed to strengthen, but there was little effect on the
height associations.
Findings from other studies on early-life body size have been
inconsistent. In all studies investigating body size early in life in
relation to later risk of endometrial cancer, body size was
retrospectively recalled; this may partly explain the equivocal
ﬁndings for both body size15–24 and height.19,21,23 Furthermore,
none of the studies evaluated if the associations differed by
histologic subtypes of endometrial cancer and they primarily
focused on body size in late adolescence making direct comparisons
difﬁcult. We found that childhood BMI was non-linearly associated
with the risk of endometrial cancer. Although studies on childhood
body size have not found similar non-linear effects, several studies
on adult BMI have found that associations were stronger or limited
to women with a BMI 427–30 kg m−2,1,4,6,33,34 whereas evidence
suggests that associations with adult height are linear. Thus, these
ﬁndings together with ours suggest that adiposity may be
especially associated with endometrial cancer risk among females
with a high level of adiposity.
Table 1. Speciﬁcation of endometrial cancers
Type Morphology (ICD-O-3) Speciﬁcation N
Oestrogen-dependenta 8140 Adenocarcinoma, NOSb 176
8210 Adenocarcinoma in tubular adenoma 4
8380 Endometrioid adenocarcinoma, NOS 659
8480 Mucinous adenocarcinoma 14
8560 Adenosquamous carcinoma 27
8570 Adenocarcinoma with squamous differentiation 40
Subtotal 920
Non-oestrogen-dependenta 8051 Verrucous carcinoma, NOS 1
8070 Squamous cell carcinoma, NOS 4
8260 Papillary adenocarcinoma, NOS 9
8310 Clear cell adenocarcinoma, NOS 18
8441 Serous cystadenocarcinoma, NOS 58
8460 Papillary serous cystadenocarcinoma 2
Subtotal 92
Unspeciﬁc 8000 Malignant neoplasm, NOS 2
8010 Carcinoma, NOS 4
8020 Carcinoma, undifferentiated, NOS 2
Subtotal 8
Total 1020
Excluded endometrial cancers 8230 Solid carcinoma, NOS 4
8246 Neuroendocrine carcinoma, NOS 1
8381 Endometrioid adenoﬁbroma 5
8800 Sarcoma, NOS 4
8890 Leiomyosarcoma, NOS 23
8896 Myxoid leiomyosarcoma 1
8930 Endometrial stromal sarcoma, NOS 8
8933 Adenosarcoma 3
8934 Carcinoﬁbroma 1
8935 Stromal sarcoma, NOS 6
8950 Mullerian mixed tumour 3
8951 Mesodermal mixed tumour 1
8980 Carcinosarcoma, NOS 30
9080 Teratoma, NOS 1
9990 No morphology 4
9999 No morphology 5
Total 100
Abbreviation: ICD, International Classiﬁcation of Disease. aOestrogen-dependent are type 1 cancers, non-oestrogen-dependent cancers are type 2 cancers.
bAdenocarcinomas NOS (not otherwise speciﬁed) were included as oestrogen-dependent cancers, as they are most likely endometrioid.
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In the adult literature, the vast majority of studies do not classify
endometrial cancer by oestrogen dependency. Among studies
distinguishing between oestrogen-dependent (type 1) and non-
oestrogen-dependent (type 2) endometrial cancers, various
deﬁnitions used are likely to contribute to some inconsistencies.
Excess adult adiposity was positively associated with both types of
endometrial cancers in some studies, nevertheless being most
pronounced for oestrogen-dependent cancers.7,10,35,36 Similarly,
adult height has also been associated with both types of
endometrial cancers, but again stronger associations were
observed with oestrogen-dependent cancers.35 We did not
observe any associations between childhood body size and non-
oestrogen-dependent cancers. Non-oestrogen-dependent cancers
are relatively uncommon, and in some studies grade 3 endome-
trioid cancers, which are oestrogen dependent, are also included
in this classiﬁcation. This may have created spurious ﬁndings in
the adult studies.
Unopposed oestrogen use increases the risk of endometrial
cancer.13,37 In sub-analyses including only non-users of unop-
posed oestrogens, the shape of the associations between child-
hood BMI and endometrioid adenocarcinoma remained similar
but the effect size seemed to increase as compared with the
analyses that did not account for unopposed oestrogen usage.
These results are consistent with the ﬁnding that the burden of
Figure 1. Hazard ratios (solid lines) and 95% conﬁdence intervals (dotted lines) for the non-linear association between childhood BMI at ages 7
and 13 years, respectively, and the risk of all endometrial cancers, oestrogen-dependent cancers and endometrioid adenocarcinomas (Cox
model stratiﬁed by 5-year birth cohorts. BMI was modelled using linear splines with two knots at z-scores of ± 0.68).
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endometrial cancer attributable to excess adult adiposity is
signiﬁcantly higher among non-oestrogen users compared with
ever users.8 It is thought that exogenous oestrogens elevate
circulating levels to such an extent that endogenous oestrogens
produced by adipose tissue only have a limited additional
inﬂuence on the risk of endometrial cancer.1,34 Associations
between height and endometrioid adenocarcinoma did not
change in analyses including only non-users of unopposed
oestrogens as expected. Results from studies on childhood body
size and endometrial cancer risk that adjusted for hormone
replacement therapy use are inconsistent, and as they did not
speciﬁcally investigate unopposed oestrogens, direct comparisons
with our study are limited.16,17,21,22
The unopposed oestrogen hypothesis is the prevailing theory
explaining associations between adiposity and endometrial cancer
risk. Adiposity may favour endometrial carcinogenesis through a
greater expression of aromatase increasing the production of
oestrogens with mitogenic effects.13,38 It is proposed that this
biological mechanism is particularly relevant among post-
menopausal women, where ovarian production of oestrogens
and progesterones has ceased.13,38 Among premenopausal
women, the obesity-related increase in ovarian androgen produc-
tion inducing a chronic anovulation leading to progesterone
deﬁciency might be most important for endometrial
carcinogenesis.13,38 In our study, we do not suspect that the
Table 2. Childhood BMI and the risk of non-oestrogen-dependent
endometrial cancer per BMI z-scorea
Age
(years)
N Cases BMI BMI adjusted for
height
Hazard
ratios
95%
conﬁdence
intervals
Hazard
ratios
95%
conﬁdence
intervals
7 145 406 84 1.03 0.81–1.30 1.00 0.78–1.27
8 147 098 86 1.17 0.92–1.49 1.15 0.90–1.48
9 142 094 85 1.13 0.89–1.45 1.11 0.86–1.42
10 138 587 87 1.23 0.97–1.57 1.20 0.94–1.55
11 137 678 86 1.25 0.97–1.60 1.23 0.95–1.59
12 136 614 86 1.30 1.02–1.66 1.30 1.01–1.68
13 134 707 88 1.31 1.03–1.66 1.31 1.02–1.68
Abbreviation: BMI, body mass index. aCox model stratiﬁed by 5-year birth
cohorts.
Figure 2. Childhood height and the risk of all endometrial cancers,
oestrogen-dependent cancers, endometrioid adenocarcinomas and
non-oestrogen-dependent cancers per z-score unadjusted (black
symbols) and adjusted (white symbols) for BMI (Cox model stratiﬁed
by 5-year birth cohorts).
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associations with childhood body size differ by menopausal state,
as the associations were the same across adult ages.
The underlying mechanisms for an association between child-
hood height and endometrial cancer risk are unknown; however,
height is a biological marker of various genetic, environmental,
hormonal and nutritional factors associated with linear growth in
childhood.1 Nevertheless, independent of the unknown mechan-
isms for these associations, our ﬁndings emphasise that endo-
metrial carcinogenesis may have its origins early in life.
In our study, we examined only the associations of child size
with endometrial cancer risk as information on adult size was
unavailable. It is likely that our ﬁndings reﬂect an admixture of
effects of childhood body size itself and the effects of size that
tracks into adult life.39 We found that the strength of the BMI and
height associations were relatively constant across childhood ages
with the exception of non-oestrogen-dependent endometrial
cancers (although the conﬁdence intervals were broad). As size
at 13 years of age is more proximal in time to adult size than
earlier size, it is expected that the associations at age 13 years
would be stronger than at 7 years if tracking entirely explained
these results. One study using recalled body size (somatotype
drawings) at age 10 years with self-reported information on
hysterectomy and HRT use found that associations with post-
menopausal endometrial cancer largely disappeared after adjust-
ing for adult BMI.24 Even though we cannot disentangle the
potential effects of tracking, our ﬁndings are important for
identifying girls who may be at later risk of developing
endometrial cancer.
The major strengths of this study include the mandatory health
exams with measurements of heights and weights among a large
group of school children. In addition, we had almost complete
long-term follow-up and due to the comprehensive Danish
registers we had extensive pathology information on a large
number of endometrial cancers making us able to classify cancers
based on their oestrogen dependency. Our study might, however,
be limited by not having information available on the age at
menarche and menopause, as a woman’s life-long number of
ovulatory cycles affects her risk of developing endometrial cancer
through the duration of exposure to endogenous sex hormones.40
We examined associations based upon single body size measures;
it was beyond the scope of this study to incorporate multiple
measures and investigate growth in relation to endometrial
cancer.
To put our results into perspective, we calculated PAFs, which
estimate the burden of endometrial cancers attributable to
childhood adiposity. In our population of girls with far lower
levels of overweight and obesity than contemporary girls, the PAF
of overweight (including obesity) of endometrioid adenocarcino-
mas was 4.0% at the age of 7 years and 3.7 % at the age of 13
years. When extrapolating our ﬁndings using levels of overweight
and obesity among girls in the latest US National Health and
Nutrition Examination Survey in 2011–2012 (35% and 34%
overweight or obese at ages 6–11 years and 12–19 years,
respectively), the PAF of overweight (including obesity) of
endometrioid adenocarcinomas was 22.3% at age 7 years and
19.8% at age 13 years.41 These values resemble the PAF estimated
for adult overweight and obesity of 34%.8 Assuming a causal
relationship, these estimates suggest there will be a tremendous
increase in numbers of future endometrial cancers given the
current high levels of childhood overweight and obesity, none-
theless, the estimates should be interpreted cautiously.
In conclusion, these results demonstrate that a greater child-
hood body size is signiﬁcantly and positively associated with the
future risk of being diagnosed with endometrial cancer, particu-
larly the oestrogen-dependent types. However, potential mechan-
isms for these associations with childhood body size warrant
further investigation. Even though most oestrogen-dependent
endometrial cancers have a good prognosis, women diagnosed
with this disease suffer from impaired physical and psychological
health, thus supporting efforts for the early identiﬁcation of
individuals at later risk of endometrial cancers to reduce the
occurrence of this disease.
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